Serum interleukin-6 associated with hepatocellular carcinoma risk: A nested case-control study

International Journal of Cancer

Volumn 134, Issue 1, 2014, Pages 154-163

  Ohishi, Waka ^a   Cologne, John B ^a   Fujiwara, Saeko ^a,b   Suzuki, Gen ^c   Hayashi, Tomonori ^a   Niwa, Yasuharu ^a   Akahoshi, Masazumi ^a   Ueda, Keiko ^a   Tsuge, Masataka ^d   Chayama, Kazuaki ^d  

^a RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^b Health Management and Promotion Center   (Japan)

^c INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

Author keywords

C reactive protein; hepatocellular carcinoma; interleukin 6; nested case control study; obesity

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6;

AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; ATOMIC BOMB SURVIVOR; BLOOD STORAGE; BODY MASS; CANCER RISK; CASE CONTROL STUDY; CITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENDER; HEPATITIS VIRUS; HEPATITIS VIRUS INFECTION; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIATION DOSE; RADIATION EXPOSURE; RISK FACTOR; SMOKING HABIT; TIME; VIRUS INFECTION;

C-REACTIVE PROTEIN; HEPATOCELLULAR CARCINOMA; INTERLEUKIN-6; NESTED CASE-CONTROL STUDY; OBESITY;

CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERLEUKIN-6; LIFE STYLE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; NUCLEAR WEAPONS; OBESITY; RISK FACTORS; SURVIVORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885953929     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28337     Document Type: Article

References (48)

1. Umemura T, Kiyosawa K,. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007; 37: S95-S100.
2. Abe H, Yoshizawa K, Kitahara T, et al. Etiology of non-B, non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol 2008; 43: 967-74.
3. Gupta K, Krishnaswamy G, Karnad A, et al. Insulin: a novel factor in carcinogenesis. Am J Med Sci 2002; 323: 140-5.
4. El-Serag HB, Tran T, Everhart JE., Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-8.
5. Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006; 166: 1871-7.
6. Caldwell SH, Crespo DM, Kang HS, et al. Obesity and hepatocellular carcinoma. Gastroenterology 2004; 127: S97-S103.
7. Marrero JA, Fontana RJ, Fu S, et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005; 42: 218-24.
8. Saunders D, Seidel D, Allison M, et al. Systematic review: the association between obesity and hepatocellular carcinoma-epidemiological evidence. Aliment Pharmacol Ther 2010; 31: 1051-63.
9. Ioannou GN, Splan MF, Weiss NS, et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 938-45.
10. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348: 1625-38.
11. Oh SW, Yoon YS, Shin SA,. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 2005; 23: 4742-54.
12. Ohishi W, Fujiwara S, Cologne JB, et al. Risk factors for hepatocellular carcinoma in a Japanese population: a nested case-control study. Cancer Epidemiol Biomarkers Prev 2008; 17: 846-54.
13. Jaiswal M, LaRusso NF, Burgart LJ, et al. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000; 60: 184-90.
14. Heikkilä K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control 2009; 20: 15-26.
15. Allin KH, Bojesen SE, Nordestgaard BG., Baseline C, reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009; 27: 2217-24.
16. Erlinger TP, Platz EA, Rifai N, et al. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004; 291: 585-90.
17. Pine SR, Mechanic LE, Enewold L, et al. Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst 2011; 103: 1112-22.
18. Chan AT, Ogino S, Giovannucci EL, et al. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 2011; 140: 799-808; quiz e11.
19. Zhang SM, Buring JE, Lee IM, et al. C-reactive protein levels are not associated with increased risk for colorectal cancer in women. Ann Intern Med 2005; 142: 425-32.
20. Nakagawa H, Maeda S, Yoshida H, et al. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer 2009; 125: 2264-9.
21. Wong VW, Yu J, Cheng AS, et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 2009; 124: 2766-70.
22. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121-4.
23. Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010; 140: 197-208.
24. Bromberg J, Wang TC,. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009; 15: 79-80.
25. Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. Clin Endocrinol Metab 2000; 85: 3338-42.
26. Fukuhara T, Sharp GB, Mizuno T, et al. Liver cancer in atomic-bomb survivors: histological characteristics and relationships to radiation and hepatitis B and C viruses. J Radiat Res 2001; 42: 117-30.
27. Ohishi W, Fujiwara S, Cologne JB, et al. Impact of radiation and hepatitis virus infection on risk of hepatocellular carcinoma. Hepatology 2011; 53: 1237-45.
28. Cologne JB, Sharp GB, Neriishi K, et al. Improving the efficiency of nested case-control studies of interaction by selecting controls using counter matching on exposure. Int J Epidemiol 2004; 33: 485-92.
29. Ohishi W, Fujiwara S, Suzuki G, et al. Feasibility of freeze-dried sera for serological and molecular biological detection of hepatitis B and C viruses. J Clin Microbiol 2006; 44: 4593-5.
30. Ohishi W, Fujiwara S, Suzuki G, et al. Validation of the use of freeze-dried sera for the diagnosis of hepatitis B and C virus infections in a longitudinal study cohort. In:, Mohan RM, ed. Research advances in microbiology 7. Kerala, India: Global Research Network, 2007. 1-9.
31. Gu Y, Zeleniuch-Jacquotte A, Linkov F, et al. Reproducibility of serum cytokines and growth factors. Cytokine 2009; 45: 44-9.
32. Young RW, Kerr GD, eds. Reassessment of the Atomic Bomb Radiation Dosimetry for Hiroshima and Nagasaki, Dosimetry System 2002, Report of the Joint US-Japan Working Group. Hiroshima, Japan: Radiation Effects Research Foundation, 2005.
33. Sharp GB, Lagarde F, Mizuno T, et al. Relationship of hepatocellular carcinoma to soya food consumption: a cohort-based, case-control study in Japan. Int J Cancer 2005; 115: 290-5.
34. The World Health Organization Western Pacific Region; The International Association for the Study; The International Obesity Task Force. The Asia-Pacific perspective: redefining obesity and its treatment. Sydney, Australia: Health Communications Australia Pty Limited, 2000.
35. Langholz B, Borgan Ø., Counter-matching: a stratified nested case-control sampling method. Biometrika 1985; 82: 69-79.
36. Breslow NE, Day NE,. Statistical methods in cancer research, vol. 1-The analysis of case-control studies. Lyon: International Agency for Research on Cancer, 1980.
37. Cologne JB, Tokuoka S, Beebe GW, et al. Effects of radiation on incidence of primary liver cancer among atomic bomb survivors. Radiat Res 1999; 153: 364-73.
38. Walsh L,. A short review of model selection techniques for radiation epidemiology. Radiat Environ Biophys 2007; 46: 205-13.
39. Sieghart W, Pinter M, Hucke F, et al. A single determination of C-reactive protein at the time of diagnosis predicts long term outcome of patients with hepatocellular carcinoma. Hepatology 2013; 57: 2224-34.
40. Zimmermann E, Anty R, Tordjman J, et al. C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. J Hepatol 2011; 55: 660-5.
41. Yoneda M, Mawatari H, Fujita K, et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007; 42: 573-82.
42. Wands J,. Hepatocellular carcinoma and sex. N Engl J Med 2007; 357: 1974-6.
43. Sander LE, Trautwein C, Liedtke C,. Is interleukin-6 a gender-specific risk factor for liver cancer? Hepatology 2007; 46: 1304-5.
44. Prieto J., Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol 2008; 48: 380-1.
45. Porta C, De Amici M, Quaglini S, et al. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 2008; 19: 353-8.
46. Grivennikov S, Karin M., Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 2008; 13: 7-9.
47. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-34.
48. Cologne J, Langholz B,. Selecting controls for assessing interaction in nested case-control studies. J Epidemiol 2003; 13: 193-202.